Background: Suboxone, a combination of buprenorphine and naloxone in sublingual tablet form, was recently approved in the United States for management of opioid dependence. Little information exists regarding the potential for opioid toxicity after Suboxone exposure in the pediatric population. We report a case of opioid toxicity after exposure to Suboxone in a pediatric patient and a review of other cases of pediatric Suboxone ingestion in the literature. Case: A previously healthy 2-year-old boy was found with 1 tablet of Suboxone (8 mg buprenorphine/2 mg naloxone) in his mouth. Remnants of the partly dissolved tablet were immediately removed from the child's oropharynx. The child experienced 1 episode of spontaneous emesis and became drowsy en route to the emergency department 30 minutes after the exposure. The patient was observed in the emergency department; no interventions were necessary, and the child was discharged asymptomatic and stable 6 hours post ingestion. Conclusion: Suboxone, a combination of buprenorphine and naloxone, may produce opioid toxicity via sublingual absorption or ingestion by children. We present the case of a child with mild central nervous system depression after exposure to Suboxone. Pediatric case reports that demonstrate more significant central nervous system and respiratory depressant effects from Suboxone ingestion are emerging.
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CASE
The California Poison Control System was contacted by the parents of a previously healthy 2-year-old boy approximately 30 minutes after he was found with 1 tablet of Suboxone (8 mg buprenorphine/2 mg naloxone) in his mouth. Remnants of the partly dissolved tablet were immediately removed from the child's oropharynx. The parents state that only 1 tablet was missing. The child experienced 1 episode of spontaneous emesis and became unusually drowsy as per the parents, who were en route to the emergency department (ED) when they contacted the California Poison Control System. No other medications were reported missing. Upon arrival to the ED, initial vital signs were the following: pulse, 137 beats per minute; blood pressure, 95/63 mm Hg; respirations, 20 per minute; temperature, 37.0 degrees; and room air oxygen saturation, 97%. On examination, the child was somnolent but arousable with pupils 1 to 2 mm and reactive. Cardiovascular status remained stable, and after 3 hours of observation, the patient was transferred to a tertiary care facility where his vital signs on arrival were the following: pulse, 145 beats per minute; blood pressure, 109/57 mm Hg; respirations, 20 per minute (unlabored); temperature, 37.0 degrees; and room air oxygenation saturation, 97%; the pupils remained 1 to 2 mm bilaterally. No naloxone was administered. The child was ambulatory at 5 hours postingestion and was discharged home 6 1 / 2 hours postexposure asymptomatic and stable.
DISCUSSION
Buprenorphine exerts its analgesic and central nervous system (CNS) and respiratory depressant effects as a partial agonist at the opioid mu receptor, but it is also an antagonist of the opioid kappa receptor. 4 Buprenorphine has better bioavailability sublingually than when ingested because of extensive first pass metabolism, but the time to peak concentration after oral or sublingual administration of Suboxone has not been established. 1, 5 Buprenorphine is hepatically metabolized to the active metabolite norbuprenorphine. In therapeutic dosing, the serum half-life of buprenorphine is 4 to 5 hours, and the elimination half-life is reported to be 37 hours. 1 The prolonged half-life and high lipophilicity of buprenorphine and potency of the metabolite norbuprenorphine may all contribute to a prolonged duration of effect. 2 Naloxone is a pure antagonist of the mu opiate receptor and is added to Suboxone to prevent intravenous or intranasal misuse. Naloxone has poor oral and sublingual bioavailability and offers little protection against buprenorphine toxicity via these routes of exposure. 1, 6 However, when given parenterally, naloxone is very effective at reversing the CNS and respiratory depressant effects of opioids such as buprenorphine. Naloxone has a plasma halflife of approximately 1.1 hours, but the duration of effect in opioid toxicity can range from 45 minutes to 4 hours. 1, 4 The respiratory and CNS depressant properties associated with buprenorphine are thought to be a result of its mixed agonist-antagonist properties and plateau with increasing doses. 2 It is important to note that, although buprenorphine's partial agonist activity demonstrates this ''ceiling effect'' in adults, this principle may not apply in the pediatric population. Until more data are available, buprenorphinecontaining compounds should be regarded as having potential for significant CNS and respiratory depression in pediatric patients.
Our patient developed minor transient signs of opioid toxicity from mucosal and sublingual exposure to single buprenorphine tablet. This relatively benign clinical course is likely due to the prompt removal of the tablet from the child's mouth. In contrast to our patient's relatively mild exposure, case reports are emerging that report significant toxicity requiring parenteral naloxone administration in pediatric Suboxone ingestions. 7, 8 A MEDLINE search using the terms Suboxone and naloxone and a review of abstracts presented at toxicology meetings since the approval of Suboxone was performed, resulting in 2 pediatric case reports. Cho et al 7 report the ingestion of 1 tablet (8 mg buprenorphine/2 mg naloxone) in a 9-month-old patient who required a total of 5 mg of naloxone and remained symptomatic for 43 hours postexposure. Gelb et al 8 reported 2 cases of Suboxone (8 mg buprenorphine/2 mg naloxone) ingestions that became symptomatic and required treatment. The first, a 16-month-old boy, presented gasping and unresponsive and required intubation and mechanical ventilation; he was hospitalized for 3 days. The second was a 22-month-old girl that presented lethargic and hypoxic, received 2 naloxone boluses followed by a continuous infusion, and was discharged 1 day postexposure. These cases and the present case demonstrate the potential for significant opioid toxicity in pediatric patients after ingestions or sublingual exposures to Suboxone.
CONCLUSIONS
Clinicians should not assume that because Suboxone is a combination of a mixed agonist-antagonist and a pure antagonist that pediatric patients are not at risk for opioid toxicity from this medication. Toxicologists, pediatricians, and ED physicians may be asked to provide treatment recommendations for unintentional pediatric exposures to Suboxone. Based on our experience, recent case reports, and the unique pharmacokinetic profile of Suboxone, we recommend that all pediatric patients with a history of exposure to Suboxone, either via ingestion or sublingual absorption, be observed in an ED. Activated charcoal may be of limited benefit because of buprenorphine's excellent sublingual absorption and rapid onset of CNS depression, potentially increasing the risk of charcoal aspiration. Parenteral naloxone should be considered if clinically significant CNS or respiratory depression develops. Patients should remain asymptomatic for at least 4 hours after naloxone administration before discharge from a health care facility.
